血漿の北米市場2020-2197

◆英語タイトル:NORTH AMERICA BLOOD PLASMA MARKET FORECAST 2020-2028
◆商品コード:INK20MY248
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年4月
◆ページ数:187
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:北米
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥131,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGSThe North America blood plasma market is estimated to project a CAGR of 6.13% during the forecast period. The region is considered to be a focal point for blood plasma therapy research and development activities, which is further assimilated into various treatment methods of the region.

MARKET INSIGHTS
The North America blood plasma market growth analysis involves the market assessment of Canada and the United States. In Canada, the potential benefits of blood plasma are explored to its fullest by several research organizations in Canada. The platelet-rich plasma (PRP) therapy has been adopted by the center for treating hair loss as a proactive approach for both male and female patients. The therapy has also proved beneficial for patients that needed hair growth stimulation, and is also a preferred method of treatment among physicians. There is also an increasing demand for plasmapheresis in the North American region, along with an increasing number of people hemophilic patients in the US, all of which boost the overall growth of the market.

COMPETITIVE INSIGHTS
Some of the bog market players having their presence in the market include, Baxter International, Bio Products Laboratory, Arthrex, Cerus Corporation (Cerus), Biotest AG, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. WIDESPREAD ACCEPTANCE OF IMMUNOGLOBULIN-BASED THERAPIES
3.2.2. GROWING USAGE OF ALBUMIN IN OTHER THERAPEUTIC AREAS
3.2.3. GROWING GERIATRIC POPULATION
3.2.4. RISING PREVALENCE OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
3.2.5. INCREASE IN THE PATIENT POOL FOR HEMOPHILIA TREATMENT
3.3. KEY RESTRAINTS
3.3.1. INCREASING USAGE OF RECOMBINANT PLASMA PRODUCTS IN THERAPEUTIC TREATMENTS
3.3.2. HIGH COSTS OF BLOOD PLASMA TREATMENTS
3.3.3. ADVERSE REACTIONS ASSOCIATED WITH POST-TRANSFUSION
3.3.4. SPREAD OF PATHOGENIC CONTAMINANTS
3.3.5. HIGH REGULATIONS IN THE MARKET
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCES ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. PLASMA THERAPEUTICS REGULATION
4.3. CLINICAL GUIDELINES
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. KEY INVESTMENT INSIGHTS
5. MARKET BY MODE OF DELIVERY
5.1. INFUSION SOLUTIONS
5.2. GELS
5.3. SPRAYS
5.4. BIOMEDICAL SEALANTS
6. MARKET BY DISORDER
6.1. IMMUNODEFICIENCY DISEASE
6.2. HYPOGAMMAGLOBULINEMIA
6.3. HEMOPHILIA
6.4. VON WILLEBRAND DISEASE (VWD)
6.5. OTHER DISORDERS
7. MARKET BY BLOOD PLASMA DERIVATIVES
7.1. IMMUNOGLOBULIN
7.1.1. INTRAVENOUS IMMUNOGLOBULIN
7.1.2. SUBCUTANEOUS IMMUNOGLOBULIN
7.1.3. OTHER IMMUNOGLOBULIN TYPES
7.2. ALBUMIN
7.3. HYPERIMMUNE
7.4. COAGULATION FACTOR CONCENTRATES
7.5. OTHER PLASMA FRACTIONATION PRODUCTS
8. MARKET BY THERAPEUTIC INDICATION
8.1. NEUROLOGY
8.2. IMMUNOLOGY
8.3. ONCOLOGY
8.4. TRANSPLANTATION
8.5. HEMATOLOGY
8.6. RHEUMATOLOGY
8.7. PULMONOLOGY
8.8. OTHER THERAPEUTIC INDICATION
9. MARKET BY END-USER
9.1. HOSPITALS AND CLINICS
9.2. RESEARCH LABORATORIES
9.3. ACADEMIC INSTITUTIONS
10. GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1. THE UNITED STATES
10.1.2. CANADA
11. COMPANY PROFILES
11.1. ADMA BIOLOGICS
11.2. ARTHREX
11.3. BIO PRODUCTS LABORATORY
11.4. BAXTER INTERNATIONAL
11.5. BIOTEST AG
11.6. CERUS CORPORATION (CERUS)
11.7. CHINA BIOLOGIC PRODUCTS
11.8. CSL LIMITED
11.9. FUSION HEALTH CARE
11.10. GREEN CROSS HOLDINGS CORPORATION
11.11. GRIFOLS
11.12. LFB
11.13. OCTAPHARMA
11.14. TAKEDA PHARMACEUTICAL COMPANY
11.15. KEDRION BIOPHARMA INC



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[血漿の北米市場2020-2197]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆